PlyGRCS Endolysin Bacterial Cell Wall Lysis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The increasing resistance of pathogenic bacteria, such as Staphylococcus aureus, to classical antibiotics necessitates the development of alternative therapeutics that can effectively treat bacterial infections without being inhibited by traditional antibiotic resistance mechanisms.

Innovation Solution

The use of endolysin polypeptides from bacteriophage GRCS, specifically PlyGRCS, which lyse bacterial cell walls upon contact, are administered to treat infections caused by Gram-positive bacteria, including methicillin- and vancomycin-resistant strains, and can be used in conjunction with secondary therapeutic agents or as part of antibacterial coatings on medical devices.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If classical antibiotics are used to treat bacterial infections, then treatment effectiveness is maintained against susceptible bacteria, but bacterial resistance develops rendering the antibiotics ineffective

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidbacterial resistance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention uses endolysin enzymes that specifically target and cleave peptidoglycan bonds in the bacterial cell wall, segmenting the cell wall structure to cause lysis. This specific enzymatic action bypasses traditional antibiotic resistance mechanisms that target protein synthesis or cell membrane function.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention replaces chemical antibiotic mechanisms with enzymatic mechanical action. Endolysins physically cleave peptidoglycan bonds through hydrolysis, a mechanical-enzymatic process that directly disrupts cell wall integrity rather than relying on chemical inhibition of bacterial processes.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Adaptability or versatility

If new antibiotics are developed to treat resistant bacteria, then alternative treatment options are provided, but resistance mechanisms continue to evolve counteracting these new agents

Engineering Contradiction:

Improvealternative treatment optionsVSAvoidresistance countermeasures

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The invention changes the fundamental parameter of antimicrobial action from chemical inhibition to enzymatic hydrolysis. Endolysins use water to break peptidoglycan bonds through hydrolysis, a different biochemical parameter that avoids resistance mechanisms evolved against chemical antibiotics.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention employs composite enzymatic formulations combining endolysin with other therapeutic agents or delivery systems. This composite approach creates synergistic effects that enhance efficacy against resistant strains while maintaining stability and reducing individual component resistance pressure.

Inventive Principle:

Principle #40Composite materials

3Adaptability or versatility

If endolysin therapy is used to treat bacterial infections, then antibiotic resistance mechanisms are circumvented, but the need for stable and effective delivery systems arises

Engineering Contradiction:

Improveresistance circumventionVSAvoiddelivery system requirements

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The invention nests endolysin enzymes within protective delivery vehicles such as liposomes, nanoparticles, or hydrogels. This nested structure protects the fragile enzymatic proteins from degradation while enabling controlled release at the infection site, reducing the complexity of external delivery infrastructure.

Inventive Principle:

Principle #7Nested doll (Nesting)

Solution Approach 2:

The invention uses intermediary delivery vehicles that mediate between the endolysin enzyme and the bacterial target. These intermediaries (e.g., targeting peptides, antibody-conjugated carriers) facilitate precise delivery to infected tissues while protecting the enzyme from premature degradation or immune clearance.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

PlyGRCS endolysin demonstrates potent antimicrobial activity against Staphylococcus species, including MRSA and VISA strains, effectively reducing bacterial populations and biofilm formation, offering a viable alternative to traditional antibiotics by circumventing resistance mechanisms.

Implementation Method 1

endolysins hydrolyze bonds in the bacterial cell wall (i.e. peptidoglycan) until lysis is complete

Methodology Applied

Scientific EffectEnzymatic hydrolysis: Hydrolysis

Data Source

PatentUS9872893B2Endolysins active against <i>Staphylococcus </i>bacteria, pharmaceutical compositions, and methods relating thereto

Publication Date: 2018.01.23 UNIV OF MARYLAND

AI summary

The present invention relates to methods of treating or preventing a bacterial disease or infection, antibacterial compositions, and antibacterial surfaces, including isolated endolysin polypeptides from bacteriophage GRCS.